Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Headquartered in Cupertino, California, the consumer electronics giant entered the smartphone market with the iPhone in 2007, and the tablet market with the iPad in 2010, and the smartwatch market ...